Icon

Webinar-Recorded

Webinar-ADCs are back stronger than ever: how, why & what’s next


Antibody-drug conjugates (ADCs) have achieved commercial success over the last ten years. ADCs offer the prospect of more precise treatments and a reduction in off-target effects, however challenges including instability remain. In this on-demand presentation, Mike Riley, President, Catalent Biologics, will discuss the latest trends in ADC discovery and development, with a focus on how next generation pipelines are being shaped by payload and linker chemistry innovations, including those from Catalent’s award-winning SMARTag® ADC platform.

Learn more about:

The challenges with first-generation ADCs

The evolution in the ADC market

How technology innovations have improved ADC stability

Line

Why Catalent?

Catalyst + Talent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of more than 7,000 products to over 1,000 customers annually. Catalent’s expert workforce exceeds 17,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™